[1] Takamura Y, Nakano K, Uruno T, et al. Changes in serum TSH receptor antibody(TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocr J, 2003, 50(5): 595-601.  doi: 10.1507/endocrj.50.595
[2]

中华医学会. 临床诊疗指南核医学分册. 北京: 人民卫生出版社, 2006: 404.
[3]

潘中允. 放射性核素治疗学. 北京: 人民卫生出版社, 2006: 94-95.
[4] 高研. Graves病诊治中的几个问题. 中华内分泌代谢杂志, 2001, 17(4): 193-194.
[5] Bojarska-Szmygin A, Janicki K, Pietura R, et al. Changes in TSH receptor antibody levels (TRAb)as markers of effectiveness of various therapies in Graves-Basedow's disease. Ann Univ Mariae Curie Sklodowska Med, 2003, 58(1): 248-253.
[6] Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin North Am, 2001, 30(2): 315-337.  doi: 10.1016/S0889-8529(05)70189-4
[7] Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab, 1998, 83(1): 40-46.
[8] Bonnema SJ, Bartalena L, Tofe AD, et al. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Ehdocrinol, 2002, 147(1): 1-11.
[9]

匡安仁, 李林. 核医学. 北京: 高等教育出版社, 2008: 109.